Document is current

Any future updates will be listed below

A phase I, open-label trial on the safety and immunogenicity of the adjuvanted tuberculosis subunit vaccine H1/IC31® in people living in a TB-endemic area

Crossref DOI link: https://doi.org/10.1186/s13063-017-2354-0

Published Online: 2018-01-10

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark